Outcomes of Pharmaceutical Care Interventions in Type 2 Diabetes Mellitus Patients: A Pre-Post Pilot Study At Federal Medical Center Abakaliki, Ebonyi State, Nigeria.

Clinical And Humanistic Outcomes of Pharmaceutical Care Interventions in Type 2 Diabetes Mellitus Patients: A Pre-Post Pilot Study At Federal Medical Center Abakaliki, Ebonyi State, Nigeria.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202311731445746

Enrollment

Registered

2023-11-28

Start date

2010-05-03

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Musculoskeletal Diseases Nutritional, Metabolic, Endocrine Kidney Disease Cardiology Orthopaedics

Interventions

Pharmaceutical care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed diagnosis of type 2 diabetes mellitus. 2. Patients on oral hypoglycaemic therapy for over six (6) months. 3. Patients with poor glycaemic and poor blood pressure and/ or poor lipid control. 4. Patients who the Consultant Endocrinologist of the hospital consented to their entry into the trial. 5. Patients who consented to the study by giving oral consent.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary forms of hypertension. 2. Patients who were pregnant 3. Patients resident outside urban settlements within the study site. 4. Patients without mobile phone numbers. 5. Patients on insulin therapy.

Design outcomes

Primary

Measure	Time frame
Glycated Haemoglobin A1c (HbA1c) measured using the In2it Analyzer model 501122R.1;Drug therapy problems were identified using a stepwise approach and a specially designed data collection sheet.;Health-related quality of life is measured using the short form – 12 (SF-12) questionnaire and evaluated using the online SF-12 Health Survey Scoring Demonstration.	—

Secondary

Measure	Time frame
Fasting Blood Sugar (FBS), measured using the Cardio-Check PA Analyzer model CE0197;Lipid profile (total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol) was measured using the Cardio-Check PA analyzer model CE0197.;10–year risk of coronary heart disease (CHD) score evaluated using online health calculators. This calculator takes account of the patient’s age, gender, smoking status, blood pressure, total cholesterol, and HDL-C.;Body mass index (BMI), is evaluated using online health calculators.;Systemic blood pressure, measured using Omron M6 Comfort Automatic Blood Pressure Monitor model HEM-7321-E;Improvement in the quality of prescribing done by the process of medication review. Here the research pharmacist discusses with the doctors regarding drug therapy and if necessary, treatment modifications were recommended as a follow-up to the pharmaceutical care plan, e.g. more intensive management of hypertension, hyperglycemia, dyslipidemia, or simplification of dosage regimen if deemed appropriate, taking account of the latest treatment guidelines. During the medication review, all drug therapy problems identified that required the attention of the physician or prescriber were presented to the consultant endocrinologist for appropriate management.	—

Measure

Time frame

Fasting Blood Sugar (FBS), measured using the Cardio-Check PA Analyzer model CE0197;Lipid profile (total cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol) was measured using the Cardio-Check PA analyzer model CE0197.;10–year risk of coronary heart disease (CHD) score evaluated using online health calculators. This calculator takes account of the patient’s age, gender, smoking status, blood pressure, total cholesterol, and HDL-C.;Body mass index (BMI), is evaluated using online health calculators.;Systemic blood pressure, measured using Omron M6 Comfort Automatic Blood Pressure Monitor model HEM-7321-E;Improvement in the quality of prescribing done by the process of medication review. Here the research pharmacist discusses with the doctors regarding drug therapy and if necessary, treatment modifications were recommended as a follow-up to the pharmaceutical care plan, e.g. more intensive management of hypertension, hyperglycemia, dyslipidemia, or simplification of dosage regimen if deemed appropriate, taking account of the latest treatment guidelines. During the medication review, all drug therapy problems identified that required the attention of the physician or prescriber were presented to the consultant endocrinologist for appropriate management.

—

Countries

Nigeria

Contacts

Public ContactPaul Olisaemeka Ezeonu

Medical Director

enquires@aefutha.gov.ng+2348035673439

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026